Skip to main content
    S

    SAB Biotherapeutics Inc (SABS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.68
    -0.15 (-5.30%)

    Market Cap: $243.84M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    40%(8/20)
    Avg Surprise
    -58.08%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.27
    Range$-0.32 - $-0.22
    5 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$-0.24-12.0%
    30d ago$-0.30+11.9%
    7d ago$-0.30+11.9%
    Current$-0.27
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.44
    Range$-0.62 - $-0.32
    5 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.44---
    Sep 26EST
    		-$-0.27---
    Jun 26
    Reported Aug 6
    		$-0.28$-0.29+3.45%Beat+74.3%
    Mar 26
    Reported May 12
    		$-0.35$-0.21-69.38%Miss+37.1%
    Dec 25
    Reported Mar 9
    		$-0.41$-0.17-141.18%Miss+58.2%
    Sep 25
    Reported Nov 14
    		$0.50$-0.46+208.70%Beat+144.6%
    Jun 25
    Reported Aug 7
    		$-1.09$-0.82-32.93%Miss-38.0%
    Mar 25
    Reported May 9
    		$-0.56$-1.07+47.66%Beat+50.9%
    Dec 24
    Reported Mar 28
    		$-0.98$-1.21+18.93%Beat+71.0%
    Sep 24
    Reported Nov 6
    		$-1.12$-1.09-2.75%Miss-10.9%
    Jun 24
    Reported Aug 8
    		$-0.79$-1.15+31.30%Beat+38.8%
    Mar 24
    Reported Apr 1
    		$-1.14$-0.98-16.33%Miss+23.0%
    Dec 23
    Reported Mar 29
    		$-3.38$-0.62-445.16%Miss-2012.5%
    Sep 23
    Reported Nov 13
    		$-1.01$-1.15+12.17%Beat+44.8%
    Jun 23
    Reported Aug 21
    		$-1.29$-1.45+11.03%Beat+14.0%
    Mar 23
    Reported Apr 14
    		$-1.48$-1.00-48.00%Miss-9.6%
    Dec 22
    Reported Mar 31
    		$-0.16$-0.16+0.00%Beat+75.8%
    Sep 22
    Reported Nov 15
    		$-1.83$-1.10-66.36%Miss-52.5%
    Jun 22
    Reported Aug 10
    		$-1.50$-1.00-50.00%Miss-4900.0%
    Mar 22
    Reported May 12
    		$-1.35$-1.10-22.73%Miss-260.7%
    Dec 21
    Reported Mar 29
    		$-0.66$-0.11-500.00%Miss-
    Sep 21
    Reported Nov 22
    		$-1.20$-0.60-100.00%Miss-
    Jun 21
    Reported Aug 9
    		$-0.03N/AN/ABeat-
    Mar 21
    Reported Apr 2
    		$0.84N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-4.94EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-11.30%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage50.20x
    Current Ratio9.22xQuick Ratio9.22x
    Trading Statistics
    Beta0.58Avg Volume735.75K
    52-Week High$5.1552-Week Low$2.10

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.95
    SMA 20$3.16
    SMA 50$3.49
    SMA 200$3.74
    EMA 10$2.95
    EMA 20$3.11
    EMA 50$3.36
    EMA 200$3.48

    MACD

    Line: -0.20Signal: -0.17Hist: -0.03

    ADX

    ADX: 30.5+DI: 11.6-DI: 26.5

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$3.14

    Bollinger Bands

    Upper Band$3.66
    Lower Band$2.66
    %B Position3170%(Upper)
    Band Width0.02

    RSI (14-Day)

    Oversold
    26.3

    Momentum Oscillators

    Stoch %K14.6
    Stoch %D16.6
    Williams %R-92.6
    ROC (10d)-16.8%
    Momentum-0.54
    CCI (20d)-141.5
    MFI (14d)50.7

    Volatility Measures

    ATR (14d)$0.19(7.1%)
    StdDev (20d)0.25
    Hist Vol46.0%(High)

    Volume Flow

    VWAP$2.72
    OBV94.1M
    AD Line-92.6M
    CMF (20d)-0.332

    Volume Metrics

    Avg Vol (20d)783.2K
    Vol Ratio1.1x
    VWMA (20d)$3.19

    Pivot Points

    R3$3.15
    R2$3.08
    R1$2.95
    Pivot Point$2.88
    S1$2.75
    S2$2.68
    S3$2.55

    Advanced Oscillators

    TSI-38.28
    Ultimate Osc39.8
    KST-168.33

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$114,698$0$263,137$944,575$305,011$1.27M
    Cost of Revenue$0$0$763,299$0$0$0$785,713$0$0$0$944,401$0
    Gross Profit$0$0$-763,299$0$0$0$114,698$0$263,137$944,575$305,011$1.27M
    Operating Expenses$23.38M$20.00M$15.77M$12.68M$9.73M$10.77M$10.12M$11.31M$10.46M$12.34M$19.18M$6.59M
    R&D$16.17M$13.40M$10.73M$8.97M$7.00M$7.66M$7.45M$7.83M$6.82M$8.15M$4.30M$4.02M
    SG&A$7.21M$6.60M$5.04M$3.71M$2.73M$3.11M$2.67M$3.48M$3.64M$4.19M$14.88M$2.57M
    Operating Income$-23,377,000$-19,997,736$-15,770,231$-12,678,969$-9,732,000$-10,772,102$-10,008,840$-11,309,366$-10,201,698$-11,390,616$-18,873,771$-5,322,922
    Interest Income$1.71M$1.05M$700,739$655,233$14,000$62,498$136,374$277,174$374,557$497,893$484,046$14,364
    Interest Expense$62,000$62,745$63,462$43,292$64,000$69,565$70,875$78,036$93,119$76,371$77,879$69,700
    Income Before Tax$-22,491,000$-18,868,885$-16,860,743$45.45M$-10,114,000$-5,196,773$-11,394,699$-10,349,410$-7,335,455$-5,025,745$-22,856,763$-5,102,317
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-22,491,000$-18,868,885$-16,860,743$45.45M$-10,114,000$-5,196,773$-11,394,699$-10,349,410$-7,335,455$-5,025,745$-22,856,763$-5,102,317
    EBITDA$-23,313,745$-19,090,592$-16,771,585$45.58M$-9,270,812$-4,430,894$-10,693,829$-9,630,044$-6,647,016$-3,546,515$-22,318,529$-4,061,535
    EBIT$-24,138,000$-19,853,337$-17,498,020$44.83M$-10,064,000$-5,189,706$-11,460,198$-10,548,548$-7,616,893$-5,447,267$-23,262,930$-5,046,981
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SABS

    News

    SAB BIO to Participate in Chardan 10th Annual Healthcare Conference

    SAB Biotherapeutics, Inc. announced its participation in the Chardan 10th Annual Healthcare Conference on October 20, 2026, where CEO Samuel J. Reich will present a fireside chat. The company...

    GlobeNewswire•10/14/26•Somewhat-Bullish

    SAB BIO to Participate in Chardan 10th Annual Healthcare Conference

    SAB Biotherapeutics, Inc. will participate in the Chardan 10th Annual Healthcare Conference on October 20, 2026. CEO Samuel J. Reich will present in a fireside chat to discuss the company's progress in developing a fully...

    GlobeNewswire•10/14/26•Somewhat-Bullish

    SAB BIO to Participate in Chardan 10th Annual Healthcare Conference

    SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company, announced its management team will participate in the Chardan 10th Annual Healthcare Conference. CEO Samuel J. Reich will present...

    The Manila Times•10/14/26•Somewhat-Bullish

    SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes

    SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced that the FDA has granted Fast Track designation for SAB-142...

    GlobeNewswire•10/13/26•Bullish

    SAB Biotherapeutics Says SAB-142 Receives FDA Fast Track Designation in Type 1 Diabetes

    SAB Biotherapeutics announced that the FDA has granted Fast Track designation to its drug candidate, SAB-142, for the treatment of Type 1 Diabetes. This designation aims to expedite the development and review of drugs...

    Yahoo Finance•10/13/26•Bullish

    SABS Valuation and Fair Value

    P/E
    -4.9x
    P/B
    1.0x
    See GNG's fair value

    SABS Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -11.3%

    SABS Competitors

    CompanyTicker
    Bicycle Therapeutics LtdBCYC
    Lifecore Biomedical Inc.LFCR
    So-Young International IncSY
    X4 Pharmaceuticals IncXFOR
    BioAge Labs, IncBIOA
    Rocket Pharmaceuticals IncRCKT
    Century Therapeutics IncIPSC
    Profound Medical CorpPROF

    Sector: Healthcare

    SABS Bull Case vs Bear Case

    Bear case

    • SABS's quarterly revenue changed -62.4% year over year.

    SABS Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    4.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.27
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 0 down

    Frequently Asked Questions About SABS

    Does SABS pay dividends?

    SAB Biotherapeutics Inc (SABS) does not currently pay a regular dividend.

    What is SABS's market cap?

    SAB Biotherapeutics Inc (SABS) has a market capitalization of $243.84M with a current stock price of $2.68.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In